Skip to content
Halazepam
Paxipam (halazepam) is a small molecule pharmaceutical. Halazepam was first approved as Paxipam on 1982-01-01. It is used to treat anxiety disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Halazepam
Tradename
Company
Number
Date
Products
PAXIPAMMerck Sharp & DohmeN-017736 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anxiety disordersEFO_0006788D001008F41.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05B: Anxiolytics
— N05BA: Benzodiazepine derivative anxiolytics
— N05BA13: Halazepam
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHALAZEPAM
INNhalazepam
Description
Halazepam is an organic molecular entity.
Classification
Small molecule
Drug classantianxiety agents (diazepam type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F
Identifiers
PDB—
CAS-ID23092-17-3
RxCUI26412
ChEMBL IDCHEMBL970
ChEBI ID—
PubChem CID31640
DrugBankDB00801
UNII ID320YC168LF (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 105 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
24 adverse events reported
View more details